Changes in Lp(a) lipoprotein levels during the treatment of hypercholesterolaemia with simvastatin

Abstract

Thirty-six patients with total serum cholesterol levels above 6.5 mmol/l and Lipoprotein(a) levels above 100 mg · 1−1 were evaluated in a 24 week double-blind, placebo controlled, cross-over study to assess the possible changes in Lp(a) during treatment with the HMG CoA reductase inhibitor simvastatin. The median plasma Lp(a) increased from 359 to 464 mg·l… (More)
DOI: 10.1007/BF02220611

Topics

3 Figures and Tables

Slides referencing similar topics